下调和上调
医学
免疫系统
细胞毒性T细胞
乳腺癌
基础(医学)
癌症研究
炎症性乳腺癌
三阴性乳腺癌
化疗
肿瘤浸润淋巴细胞
病态的
免疫学
癌症
免疫疗法
病理
内科学
生物
基因
体外
胰岛素
生物化学
作者
François Bertucci,Pascal Finetti,Daniel Birnbaum,Émilie Mamessier
出处
期刊:OncoImmunology
[Informa]
日期:2015-08-31
卷期号:5 (3): e1085148-e1085148
被引量:41
标识
DOI:10.1080/2162402x.2015.1085148
摘要
Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with a better pathological response to chemotherapy in these subtypes and IBC. Reactivation of dormant tumor-infiltrating lymphocytes (TILs) by PD1/PDL1-inhibitors represents a promising strategy in these aggressive tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI